Strategic partnering evolves in new PRA Health Sciences-Takeda agreement
PRA Health Sciences and Takeda Pharmaceutical have entered into a new partnership agreement. The global CRO will serve as Takeda’s primary strategic partner to manage an entire pipeline of studies across phases I-IV and provide operational services for both development and marketed product portfolios. Andy Plump, M.D., Ph.D., Takeda’s chief medical and scientific officer, said, "It represents a truly innovative approach to clinical development, unprecedented in our industry.”
Site network expansions: An industry trend?
Two new alliances have joined a slew of other site acquisitions throughout recent months. Woodlands Medical Specialists will join The US Oncology Network and BTC Network has acquired Lincoln Research.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.
